STOCK TITAN

Haleon (NYSE: HLN) plans 7.1p 2025 dividend after strong FCF

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Haleon plc has made its preliminary full year results for the year ended 31 December 2025 available online and through the UK Financial Conduct Authority’s National Storage Mechanism. The statement can be accessed via the Haleon investor website and London Stock Exchange document link.

Reflecting strong free cash flow and organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share, a payout ratio of about 38% of 2025 adjusted earnings versus 37% in 2024. This includes a final dividend of 4.9p per share, subject to shareholder approval, with payment on 14 May 2026 to holders on the register as of 10 April 2026. The ex-dividend date is 9 April 2026 for ordinary shares and 10 April 2026 for ADSs, and DRIP elections are due by 24 April 2026. Haleon states it expects to grow its ordinary dividend at least in line with adjusted earnings.

A recorded results presentation by the CEO and CFO will be available from 7:00am GMT on 25 February 2026, followed by a Q&A call at 8:45am GMT with international dial-in access and a later archived webcast on the investor website.

Positive

  • None.

Negative

  • None.
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of February 2026
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
25 February 2026 - “Haleon Preliminary 2025 Full Year Results”
99.2
25 February 2026 - “Haleon Preliminary 2025 Full Year Results
 
 
99.1
 
Haleon plc: Preliminary 2025 Full Year Results
 
25 February 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its preliminary full year results statement for the year ended 31 December 2025 is available at http://www.rns-pdf.londonstockexchange.com/rns/2433U_1-2026-2-24.pdf.
 
The preliminary full year results statement will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
Dividend
Reflecting the strength of FCF generation during the year, alongside strong organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share which represents a payout ratio of approximately 38% of 2025 adjusted earnings (2024: 37%). This includes a final dividend of 4.9p per ordinary share.
 
Subject to shareholder approval, the final dividend will be paid on 14 May 2026 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 10 April 2026 (the record date). The ex-dividend date for ordinary shares will be 9 April 2026 and for US American Depositary Shares (ADS) 10 April 2026. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline will be 24 April 2026. The DRIP is provided by Equiniti Financial Services Limited, more information is available at www.shareview.co.uk/info/drip.
 
Subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.
 
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7:00am GMT (8:00 am CET) on 25 February 2026 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 8:45am GMT (9:45am CET).
 
For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:
 
 
UK:
+44 (0) 808 189 0158
US:
+1 855 979 6654
All other:
+44 (0) 203 936 2999
Passcode:
049869
 
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
 
This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.
 
Amanda Mellor 
Company Secretary 
 
 
Enquiries
 
Investors
Media
 
Jo Russell
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information please visit www.haleon.com.
                        
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: February 25, 2026
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
 
 

FAQ

What did Haleon plc (HLN) announce in its February 2026 Form 6-K?

Haleon announced that its preliminary full year results for 2025 are available online and via the UK regulator’s storage system. The filing also details a proposed 2025 total dividend, key dividend dates, and information on the investor presentation and Q&A session.

What is Haleon plc’s proposed 2025 total dividend per share?

Haleon is proposing a 2025 total dividend of 7.1p per ordinary share. This represents a payout ratio of approximately 38% of 2025 adjusted earnings, compared with 37% in 2024, and includes a final dividend of 4.9p per ordinary share.

When will Haleon’s 2025 final dividend be paid and what is the record date?

Subject to shareholder approval, Haleon’s 2025 final dividend of 4.9p per share will be paid on 14 May 2026. The record date is 10 April 2026 for ordinary shares and American Depositary Shares, with ex-dividend dates of 9 April and 10 April respectively.

How does Haleon’s 2025 dividend payout compare with the prior year?

Haleon’s proposed 2025 total dividend of 7.1p per share equates to a payout ratio of about 38% of adjusted earnings. This is slightly higher than the 37% payout ratio reported for 2024, indicating a modest increase in the proportion of earnings returned to shareholders.

What is Haleon’s stated policy on future dividend growth?

Haleon states that, subject to market conditions and Board approval, it expects to grow its ordinary dividend at least in line with adjusted earnings. This indicates an intention to align dividend growth with underlying profit performance rather than setting a fixed cash amount.

When is Haleon’s 2025 results presentation and Q&A for investors?

A recorded results presentation by Haleon’s CEO and CFO will be available shortly after 7:00am GMT on 25 February 2026. This will be followed by a live Q&A session at 8:45am GMT, with international dial-in numbers and an archived webcast accessible via the company’s investor website.

How can Haleon shareholders participate in the Dividend Reinvestment Programme (DRIP)?

Ordinary shareholders wishing to participate in Haleon’s DRIP must submit elections by 24 April 2026. The DRIP is provided by Equiniti Financial Services Limited, and further information is available on the Shareview website, allowing shareholders to reinvest cash dividends into additional shares.

Filing Exhibits & Attachments

1 document
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

47.92B
4.45B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge